TEMELIMAB ( DrugBank: Temelimab )


1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica4

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,342 Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05049161
(ClinicalTrials.gov)
August 27, 202131/8/2021A Long-term Extension of Study GNC-401A Long-term Extension of Study GNC-401 With Temelimab in Patients With Relapsing Forms of Multiple Sclerosis (RMS) Under Treatment With RituximabMultiple SclerosisDrug: Temelimab 18 mg/kg;Drug: Temelimab 36mg/kg;Drug: Temelimab 54 mg/kgGeNeuro Innovation SASNULLRecruiting18 Years55 YearsAll40Phase 2Sweden
2EUCTR2021-001973-21-SE
(EUCTR)
09/07/202104/06/2021Extension of Study GNC-401 with temelimab in patients with Multiple Sclerosis under treatment with rituximabA long-term extension of Study GNC-401 with temelimab in patients with Relapsing forms of Multiple Sclerosis (RMS) under treatment with rituximab - ProTEct-MS Extension Multiple Sclerosis
MedDRA version: 21.0;Level: PT;Classification code 10080700;Term: Relapsing multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Temelimab
Product Code: GNbAC1
INN or Proposed INN: TEMELIMAB
Product Name: Temelimab
Product Code: GNbAC1
INN or Proposed INN: TEMELIMAB
Product Name: Temelimab
Product Code: GNbAC1
INN or Proposed INN: TEMELIMAB
GeNeuro Innovation SASNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Phase 2Sweden
3NCT04480307
(ClinicalTrials.gov)
June 17, 202010/7/2020Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple SclerosisA Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis (RMS)Multiple SclerosisDrug: temelimab 18 mg/kg;Drug: temelimab 36 mg/kg;Drug: temelimab 54 mg/kg;Drug: PlaceboGeNeuro Innovation SASNULLActive, not recruiting18 Years55 YearsAll41Phase 2Sweden
4EUCTR2019-004822-15-SE
(EUCTR)
18/05/202017/01/2020A Clinical Trial Examining the Effects of Temelimab Following Rituximab Treatment in Patients with Multiple SclerosisA Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients with Relapsing Forms of Multiple Sclerosis (RMS) - ProTEct-MS Multiple Sclerosis
MedDRA version: 21.0;Level: PT;Classification code 10080700;Term: Relapsing multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Temelimab
Product Code: GNbAC1
INN or Proposed INN: temelimab
Product Name: Temelimab
Product Code: GNbAC1
INN or Proposed INN: temelimab
Product Name: Temelimab
Product Code: GNbAC1
INN or Proposed INN: temelimab
GeNeuro Innovation SASNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Phase 2Sweden